Introduction
Changes in strategies for the prevention and treatment of postoperative recurrence (POR) of Crohn’s disease (CD) over recent decades have resulted in improved long-term prognosis. However, it remains unclear whether the role of surgery in the biologic era, advances in surgical techniques, and prior exposure to advanced therapies may have modified the natural history of POR.
Aims & Methods
Aim: To assess endoscopic (ePOR) and clinical (cPOR) postoperative recurrence over the last three decades in patients with CD who underwent surgical resection without subsequent prophylaxis or treatment.
Methods: We performed a systematic review and meta-analysis of published controlled clinical trials on POR prevention that included a placebo group. Data were collected regarding study design, characteristics of the included populations, and endoscopic and clinical POR rates in placebo groups. Pooled values of POR rate, when available in the selected studies, were estimated using the random effects meta-analysis model. Pooled values were reported as overall proportion from studies reporting a single proportion with 95% confidence intervals. Statistical heterogeneity was assessed by the test and complemented with the index. Leave-one-out sensitivity analysis was performed when high statistical heterogeneity A subgroup analysis was conducted to estimate the overall effect on follow-up time and year of publication. A meta-regression analysis was conducted to examine the influence of known risk factors on outcome rate
Results
Twenty out of 39 identified studies were included. Regarding study design, only one selected a high-risk population, three included only first surgeries, four used centralized endoscopy reading, and nineteen used the Rutgeerts score. Concerning risk factors, perianal disease rate was available in 2 studies, penetrating phenotype in 7, and smoking status in 12. Prior exposure to immunomodulators was available in 7 studies and to biologics in 13. Among these variables, only the availability of smoking data was lower in pre-2000 studies. No differences were observed in the mean disease duration at the time of surgery across the three periods. ePOR and cPOR rates are shown in Table 1. In the meta-regression analyses, risk of ePOR at 6 months was significantly correlated with the year of publication (more recent, more risk) (0.07 [CI95% 0.01-0.14]; p=0.016), whereas risk for severe ePOR at 6 months was significantly correlated with the year of publication (more recent, more risk) (0.05 [CI95% 0.00-0.11]; p=0.039), proportion of active smokers (9.4 [CI95% 3.2-16]; p=0.003) and proportion of first resections (-8.3 [CI95% -12 - -4.1]; p<0.001).
Table 1. Endoscopic and Clinical Postoperative Recurrence Rates Over Time (Placebo Groups Only)
| Outcome | Before 2000 | 2001–2010 | After 2010 | I² | P |
ePOR at 3 months (7 studies) | 0.43 (0.34–0.52) | 0.47 (0.33–0.62) | 0.47 (0.33–0.62) | 35% | 0.16 |
ePOR at 6 months (4 studies) | — | 0.64 (0.49–0.77)* | 0.83 (0.75–0.89) | 66% | 0.031 |
ePOR at 12 months (5 studies) | 0.60 (0.52–0.67) | 0.79 (0.61–0.91) | — | 27% | 0.24 |
| Severe ePOR at 3 months (4 studies) | 0.14 (0.06–0.26)* | 0.12 (0.06–0.25) | 0.16 (0.07–0.29)* | 0% | 0.90 |
| Severe ePOR at 6 months (4 studies) | 0.06 (0.01–0.17)* | 0.23 (0.12–0.39)* | 0.15 (0.09–0.25) | 40% | 0.17 |
| Severe ePOR at 12 months (3 studies) | 0.32 (0.13–0.59) | 0.18 (0.04–0.43)* | — | 79% | 0.01 |
cPOR at 12 months (6 studies) | 0.27 (0.21–0.34) | 0.22 (0.07–0.50) | — | 15% | 0.32 |
cPOR at 24 months (4 studies) | 0.30 (0.21–0.42) | 0.45 (0.29–0.62)* | — | 55% | 0.10 |
cPOR at 36 months (4 studies) | 0.43 (0.34–0.53) | 0.47 (0.32–0.64)* | 0.23 (0.16–0.32)* | 77% | 0.05 |
Conclusion
Patients with CD included in RCT for POR prevention showed an increased risk of ePOR and severe ePOR over time. Variations in POR are also influenced by the proportion of active smokers and first intestinal resections. Studies with individual data of large prospective cohorts are warranted to unravel the underlying causes.
Disclosure
GP has served as a speaker or has received research funding from Adacyte Therapeutics, Janssen, Kern Pharma, Tillots, and Ferring